VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing medicines for central nervous system (CNS) diseases, was granted Fast Track designation by the U.S. FDA for the company’s PH94B neuroactive nasal spray for on-demand treatment of social anxiety disorder (SAD).   The FDA’s Fast Track process is designed to facilitate the development and review of new treatments for serious conditions with unmet medical need, with the goal of getting new treatment opti...